When comparing these markers with disease outcome, FOXP3 was significantly greater in patients with a good compared to poor outcome in stage II CRC (p = 0.0037; Figure 6A), whilst no statistical differences were observed in stage III CRC (Figure 6B). The gene discussed is FOXP3; the disease is colorectal carcinoma.